20 January 2015:
Recipharm is pleased to announce the appointment of Anke Mollowitz to the role as Key Account Director. Anke has joined the Business Management team and is responsible for coordinating customer management and commercial aspects, as well as developing relationships with a selected number of customers in Europe.
This new role expands Recipharm’s sales organisation and is a further step to proactively build client networks and develop a deep understanding of the customers’ business as well as initiate new business opportunities for the Recipharm Group.
After Anke’s professional education as translator and interpreter, she worked for more than 13 years in sales in a company manufacturing machines for the timber processing industry. In 2005 she joined Haupt Pharma Wülfing GmbH, member of the Aenova group since 2014. After working as sales representative and project manager, she took the position as Head of Customer Service in 2013. Among other tasks she was responsible for acquisitions and business development within the Haupt Group. In March 2015 she became part of the Aenova sales team in addition to her responsibility as Head of Customer Service. In this position she was first contact for specific key accounts and accounts in order to enlarge existing business and generate new business for all sites of the Aenova Group.
Commenting on the appointment, Kenth Berg VP Business Management said: “I am very pleased that Anke has joined the Business Management team. With extensive knowledge and experience in the CDMO business, her contribution will be very valuable in the development of our customer relationships. Contact information
Kenth Berg, VP Business Management, kenth.berg@recipharm.com, + 46 8 602 52 00
Anke Mollowitz, Key Account Director, anke.mollowitz@recipharm.com, +49 151 42 48 92 13
For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on: E-mail:
t.jervis@defacto.com or a.heeley@defacto.com
Tel: +44 (0) 203 735 8166/8165
About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,200 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 3.4 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com
